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1  | INTRODUC TION
Obstructive sleep apnea (OSA) is a common condition among over-
weight and obese individuals.1 About half of patients with OSA have 
hypertension, and about half of patients with hypertension have OSA.2 
Causal link between OSA and hypertension is complex and remains de-
batable, but hypertension may in part arise from increased sympathetic 
nerve activity induced by hypoxic stress.3 OAS is associated with a num-
ber of secondary health complications, most notably cardiovascular dis-
ease,4 and co-existing cardiometabolic risk factors such as dyslipidemia, 
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Stress from obstructive sleep apnea (OSA) stimulates catecholamine release conse-
quently exacerbating hypertension. However, different studies have shown a con-
flicting impact of continuous positive airway pressure (CPAP) treatment in patients 
with OSA on catecholamine levels and blood pressure. We aimed to examine changes 
to catecholamine levels and blood pressure in response to CPAP treatment. We con-
ducted a meta-analysis of data published up to May 2020. The quality of the stud-
ies was evaluated using standard tools for assessing the risk of bias. Meta-analysis 
was conducted using RevMan (v5.3) and expressed in standardized mean difference 
(SMD) for catecholamines and mean difference (MD) for systolic (SBP) and diastolic 
blood pressure (DBP). A total of 38 studies met our search criteria; they consisted 
of 14 randomized control trials (RCT) totaling 576 participants and 24 prospective 
cohort studies (PCS) of 547 participants. Mean age ranged between 41 and 62 year 
and body mass index between 27.2 and 35.1 kg/m2. CPAP treatment reduced 24-
hour urinary noradrenaline levels both in RCT (SMD = −1.1; 95% confidence interval 
(CI): −1.63 to − 0.56) and in PCS (SMD = 0.38 (CI: 0.24 to 0.53). SBP was also reduced 
by CPAP treatment in RCT (4.8 mmHg; CI: 2.0-7.7) and in PCS (7.5 mmHg; CI: 3.3-
11.7). DBP was similarly reduced (3.0 mmHg; CI: 1.4-4.6) and in PCS (5.1 mmHg; CI: 
2.3-8.0). In conclusion, CPAP treatment in patients with OSA reduces catecholamine 
levels and blood pressure. This suggests that sympathetic activity plays an intermedi-
ary role in hypertension associated with OSA-related stress.
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endothelial dysfunction, deranged inflammatory responses, and insulin 
resistance5; all of which are associated with obesity.6
The main treatment for OSA is continuous positive airway pres-
sure (CPAP). Meta-analyses have shown CPAP slightly reduces ar-
terial blood pressure.7,8 However, studies on the impact of CPAP 
treatment on sympathetic activity markers such as catecholamines 
have drawn conflicting conclusions.9-11 There is a lack of meta-anal-
yses on large numbers of participants recording the effects of CPAP 
in the same individuals on both changes in catecholamine levels 
and blood pressure. This information is important as it provides ev-
idence of sympathetic activity as a mediator of OSA-related stress 
and hypertension.
We therefore conducted a meta-analysis of published data to 
document changes in the levels of catecholamines and their inactive 
metabolites [metadrenalines], as well as blood pressure in response 
to CPAP treatment of OSA.
2  | METHODS
2.1 | Search criteria
Two investigators followed PRISMA12 and Cochrane guidelines,13 
and performed independently a literature search of MEDLINE and 
Google Scholar up to May 2020 using the key terms (British or US 
usage and abbreviations, eg, CPAP and OSA): obstructive sleep 
apnea, continuous positive airway pressure, urinary or plasma 
catecholamines, adrenaline (epinephrine), noradrenaline (norepi-
nephrine), 3-methoxytyramine, metanephrines, normetanephrine, 
metanephrine and dopamine, and hypertension. No filters for lan-
guage or data were used. The Boolean operators “AND” and “OR” 
were used to combine search terms. Relevant studies were hand-
searched within these references.
2.2 | Selection criteria
Studies examining the effect of CPAP on catecholamines in the OSA 
population were included irrespective of age, sex, race, comorbidi-
ties, duration of CPAP, and treatment. Studies that fit the inclusion 
criteria were randomized control trials (RCTs) and prospective co-
hort studies (PCS). Studies were excluded if they did not present 
numerical data for catecholamines at baseline and end point.
2.3 | Outcome measures
24-hour urinary or plasma catecholamines: dopamine, adrenaline 
and noradrenaline, or their products metadrenalines (metane-
phrines): 3-methoxytyramine, normetadrenaline (normetanephrine) 
and metadrenaline (metanephrine) and blood pressure were the out-
comes used for the comparison analysis.
2.4 | Risk of bias
The quality of the reports was evaluated using the risk of bias as-
sessed using Cochrane Collaboration's tool for RCTs14 and risk of 
bias in non-randomized studies of interventions (ROBINS-I) tool for 
PCS.15 The risk of bias for each report was rated independently from 
low, moderate, serious, or critical by two authors, and any discrepan-
cies were resolved by reciprocal discussion.
F I G U R E  1   QUOROM (quality of 
reporting of meta-analyses) flow chart of 
literature search
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TA B L E  1   Baseline characteristics of participants
Sex (M/F)
Mean ± SD (or range where indicated)
CPAP 
durationAge (years) BMI (kg/m2) SBP (mmHg) DBP (mmHg)
RCT (CPAP group)
Arias et al (2008)a 18 30/0 52 ± 13 30.5 ± 4.0 121.5 ± 11.4 74.5 ± 7.8 3 mo
Casitas et al (2017)a 19 26/6 56 ± 11.2 29.2 ± 5.6 131.5 ± 12.0 78.8 ± 8.5 12 wk
Comondore et al (2008)a 20 9/4 55 ± 7.1 31.1 138.4 83.8 4 wk
de Araújo et al (2013)21 8 (Both) 43 ± 12 28 ± 4 112 ± 12 67 ± 8 1 night
Drager et al (2007)27 12/0 44 ± 7 29.9 ± 3.0 123 ± 12 73 ± 10 4 mo
Kohler et al (2008)28 51/0 48.1 ± 9.5 35.8 ± 7.3 131.3 ± 13.9 83.9 ± 9.3 4 wk
Lam et al (2010)22 31/0 46.5 ± 10.8 27.8 ± 3.7 130.8 ± 14.7 80.1 ± 10.8 4 wk
Mansfield et al (2004)23 28/0 57.2 ± 9 33.5 ± 4.8 99 ± 15.9b  105 ± 15.9b  3 mo
Mills et al (2006)24 15/2 47.6 ± 10.7 31.7 ± 5.8 155.2 ± 18.6 84.2 ± 10.7 2 wk
Phillips et al (2011)a 25 35/3 49 ± 13 32.1 ± 4.3 – – 2 mo
Rubinsztajn et al (2006)29 15/0 50.6 ± 10.0 31.5 ± 6.3 130.1 ± 17.8 87.3 ± 13.5 8 mo
Ruzicka et al (2020)30 7/0 59 (58-67)c  33 (31-35) c  140 (136-165)c  73 (66-85)c  6 wk
Ryan et al (2005)26 9/1 57.6 ± 7 28.3 ± 4.1 120.7 ± 17.1 64.6 ± 9.5 1 mo
Thunstrom et al (2016)31 15/9 58 ± 6.7 27.7 ± 3.2 164.9 ± 16.2 96.5 ± 10.9 6 wk
RCT (control group)
Arias et al (2008)a 18 30/0 52 ± 13 30.5 ± 4.0 121.5 ± 11.4 74.5 ± 7.8 3 mo
Casitas et al (2017)a 19 26/6 56 ± 11.2 29.2 ± 5.6 131.5 ± 12.0 78.8 ± 8.5 12 wk
Comondore et al (2009)a 20 9/4 55 ± 7.1 31.1 138.4 83.8 4 wk
de Araújo et al (2013)21 8 (Both) 43 ± 12 28 ± 4 112 ± 12 67 ± 8 1 night
Drager et al (2007)27 12/0 47 ± 6 29.7 ± 2.9 123 ± 12 73 ± 10 4 mo
Kohler et al (2008)28 51/0 48.7 ± 10.6 34.5 ± 5.0 138.9 ± 20.8 88.3 ± 8.1 4 wk
Lam et al (2010)22 30/0 46.1 ± 9.8 27.2 ± 3.7 129.5 ± 16.5 82.0 ± 11.6 4 wk
Mansfield et al (2004)23 24/3 57.5 ± 8.3 34.6 ± 6.2 99 ± 15.9b  105 ± 15.9 3 mo
Mills et al (2006)24 13/3 49 ± 10.4 32.2 ± 6.8 149 ± 23.2 83.6 ± 13.6 2 wk
Phillips et al (2011)a 25 35/3 49 ± 13 32.1 ± 4.3 – – 2 mo
Rubinsztajn et al (2006)29 10/0 45.4 ± 16.5 27.6 ± 3.1 126.7 ± 12.3 84.2 ± 10.0 8 mo
Ruzicka et al (2020)30 6/0 63 (55-71)c  34 (33-36)c  138 (127-148)c  71 (62-81.5)c  6 wk
Ryan et al (2005)26 7/1 60.3 ± 11.6 35.1 ± 10.5 139 ± 15.6 69.9 ± 12.2 1 mo
Thunstrom et al (2016)31 17/6 59 ± 3.7 27.6 ± 4.1 164.9 ± 16.2 96.5 ± 10.9 6 wk
Prospective cohort studies
Baruzzi et al (1991)32 6/0 41.3 ± 12.9 36 ± 6 – – 1 night
Bischof et al (2019)57 18/0 55.8 ± 9.5 35.5 ± 3.8 133.2 ± 14.1 80.2 ± 10.6 6 mo
Bratel et al (1999)33 16/0 51.3 ± 10.8 32.0 ± 5.6 143.8 ± 17.2 87.5 ± 10 7 mo
Burioka et al (2008)58 8/0 45.9 ± 12.2 25.9 ± 1.7 – – 3 mo
Castro-Grattoni et al (2017)34 48/12 52.3 ± 9.56 30.7 ± 4.2 122.7 ± 9.9 77.2 ± 7.7 6 mo
Donadio et al (2007)45 10/0 50 ± 9.5 32 ± 6.3 144 ± 6.3 98 ± 3.2 6 mo
Feres et al (2014)35 6/3 56.0 ± 15.6 – – – 1 y
Ferrier et al (2008)36 16/3 58.5 ± 11.2 30.2 ± 6.7 132 ± 16 80 ± 9 6 mo
Grimpen et al (2000)59 26/3 56.9 ± 8.6 29.5 ± 3.8 98.4 ± 2.7b  98.4 ± 2.7b  14 mod 
Heitmann et al (2000)60 18 (Both) 50.0 ± 10.4 29.7 ± 3.7 136.8 ± 15.7 84.9 ± 12.5 42 dd 
Jennum et al (1989)46 13/1 42 (36-66) c  26.13 ± 3.5 147.5 ± 5.2 122.4 ± 4.3 1 wk
Kita et al (1998)37 12/2 53 ± 14.5 29.9 ± 4.9 127.6 ± 19.8 77.8 ± 11.6 1 night
Krieger et al (1989)38 20/1 51 ± 10.1 32.0 ± 1.3 – – 1 night
(Continues)
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2.5 | Statistical analysis
Meta-analysis was performed using Review Manager (RevMan, 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, the 
Cochrane Collaboration, 2014). The standardized mean difference 
(SMD) was used to determine the effect size on catecholamines to 
accommodate for a variety of ways they were measured. The SMD 
expresses the size of the intervention effect in each study relative 
to the variability observed in that study. The mean difference (MD) 
used on the original scale of measurement to determine the effect 
size on blood pressure. Pooled estimates of each outcome for each 
treatment were obtained via the DerSimonian and Laird method 
using a random-effects model.16 Statistical significance threshold 
was accepted as P < .05. The I2 statistic was used to assess het-
erogeneity of trial results used to construct pooled estimates of 
effect. 17
RESULTS
A total of 38 studies met the above search criteria: 14 RCT18-31 
including a total of 576 participants (295 in treatment groups and 
281 controls) and 24 PCS,32-35 totaling 547 participants (Figure 1). 
The mean age ranged between 41 and 62 yr and body mass index 
between 27.2 and 35.1 kg/m2 (Table 1). The remaining baseline 
parameters including heart rate, sleep study characteristics, and 
noradrenaline levels are shown in Table S1. The duration of CPAP 
treatment ranged from one day to eight months in RCTs and one 
day to a year in PCS. Most studies used 24-hour urinary noradren-
aline as outcome measure, including nine RCTs18-26 and 13 PCS.32-
44 A fewer RCTs and PCS, respectively, reported 24-hour urinary 
adrenaline (n = 6 and 7), normetadrenaline (n = 3 and 0) and 
metadrenaline (n = 2 and 0), or plasma noradrenaline (n = 5 and 
13) and adrenaline (n = 3 and 6) (Table 2). Subsequently, data from 
studies on 24-hour urinary noradrenaline are presented herein 
while the remaining data on other methods of measurement of 
catecholamines and their metabolites are shown in Figures S1 and 
S2.
Sex (M/F)
Mean ± SD (or range where indicated)
CPAP 
durationAge (years) BMI (kg/m2) SBP (mmHg) DBP (mmHg)
Lemmer et al (2016)47 17/0 60.5 ± 8.1 35.0 ± 4.7 138 ± 15.2 83.3 ± 10.2 8 wk
Minemura et al (1998)39 26/0 47.8 ± 11.1 30.6 ± 5.1 125 ± 15 80 ± 10.9 1 night
Mokhlesi et al (2017)61 6/6 54.6 ± 10.2 37.7 ± 8.7 – – 1 wk
Myhill et al (2012)40 27/17 66.1 ± 8.8 33.6 ± 5.5 149 ± 23 80 ± 12 3 mo
Nakamura et al (2001)62 18/0 49.9.3 29.9 ± 5.1 119.9 ± 16.1 84 ± 11.9 1 night
Nicholl et al (2018)48 17/8 49 ± 10 33.5 ± 6.5 127 ± 10 79 ± 10 4 wk
Pinto et al (2013)41 67/0 49.4 ± 8.8 31.8 ± 5.3 124.7 ± 12.6 77.8 ± 9.2 1 mo
Rodenstein et al (1992)63 11/1 50.0 ± 9.0 36.9 ± 8.6 – – 2-3 nights
Sukegawa et al (2005)42 17/0 53.1 ± 13.5 26.7 ± 4.8 – – 1 night
Tachikawa et al (2016)43 51/12 60.6 ± 10.0 27.9 ± 3.8 – – 3 mo
Unterberg et al (2005)44 9/1 61 (50-69) c  33 (27-46) c  – – 3 nights
Abbreviations: BMI, body mass index; CPAP, continuous positive airway pressure; M/F, male/female; RCT, randomized controlled trial; SBP and DBP, 
systolic and diastolic blood pressure.
aCrossover study. 
bMean arterial pressure. 
cRange. 
dMean values. 
TA B L E  1   (Continued)
TA B L E  2   Number of studies and participants reporting 
24-hurinary or plasma tests to determine catecholamines or their 
metabolites, and blood pressure
Studies (n) Participants (n)
Randomized controlled trials 
(n = 14)
Case/control
24-h urinary noradrenaline 9 186/180
24-h urinary adrenaline 6 140/135
24-h urinary normetadrenaline 3 92/87
24-h urinary metadrenaline 2 41/36
Plasma noradrenaline 5 24/23
Plasma adrenaline 3 46/39
Blood pressure 10 208/199
Prospective cohort studies (n = 24)
24-h urinary noradrenaline 13 367
24-h urinary adrenaline 7 173
24-h urinary normetadrenaline – –
24-h urinary metadrenaline – –
Plasma noradrenaline 13 269
Plasma adrenaline 6 85
Blood pressure 10 297
Note: NB: Some studies reported more than one test.
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CPAP treatment reduced the levels of 24-hour urinary nor-
adrenaline levels both in RCT: SMD = −1.1 (95%CI = −1.63 
to − 0.56) (Figure 2A) and in PCS: SMD = 0.38 (95%CI = 0.24 to 
0.53) (Figure 2B). Inter-study heterogeneity was high among RCT 
(I2 = 81%) but low among PCS (I2 = 0%).
Blood pressure as study outcome measure was reported in ten 
RCTs totaling 407 participants18-22,24-28,30 and ten PCS containing 
297 participants34,36,39-41,45-48 (Table 2). CPAP treatment led to a 
blood pressure reduction. With RCT, mean reductions of SBP were 
4.8 mmHg (95%CI = 2.0-7.7 mmHg) (Figure 3A) and of DBP were 
3.0 mmHg (95%CI = 1.4-4.6 mmHg) (Figure 3B). With PCS, mean 
reductions of SBP were 7.5 mmHg (95%CI = 3.3 to 11.7 mmHg) 
(Figure 3C) and of DBP were 5.1 mmHg (95%CI = 2.3-8.0 mmHg) 
(Figure 3D). There was evidence of substantial inter-study hetero-
geneity both in RCTs (I2 = 84% and 62%, respectively, in SBP and 
DBP analyses) and in PCS (I2 = 71% and 64%, respectively, in SBP 
and DBP analyses).
We have also observed that CPAP had similar impact on the re-
duction of other catecholamines and their metabolites (Results not 
shown).
Risk of bias for the RCT assessed by random sequence genera-
tion (Figure 4A) showed a high risk in three studies since they were 
not double-blinded.20,21,23 All of the studies used intention-to-treat 
analysis or did not have any dropouts, to minimize risk of incomplete 
outcome data. All of the studies lacked information of selective re-
porting bias as they did not mention the study protocol. There were 
confounding factors in one study21 due to all of the patients un-
dergoing surgery and in another23 where patients were undergoing 
heart failure treatment.
Risk of bias for PCS was evaluated using the risk of bias in non-ran-
domized studies of interventions (ROBINS-I) tool (Figure 4B). Bias 
due to confounding factors was seen in five studies,36,39,39,44 but in 
only three was there a moderate risk of overall bias.35,39,44 Patients 
in one study44 had previously been receiving CPAP therapy for at 
least three months. Bias in selection of participants was seen in 
one study: There was no reimbursement for CPAP usage in Brazil.35 
Missing data were assessed to cause a moderate risk of bias in three 
studies.34,35,39 None of the studies had bias in measurement of out-
comes. There was insufficient information from any of the studies 
for assessing bias in selection of the reported result.
3  | DISCUSSION
In this meta-analysis of data from over a thousand patients with 
OSA, it was observed that CPAP treatment significantly reduced 
F I G U R E  2   Changes in 24-hour urinary noradrenaline levels by CPAP treatment in RCT (A) and in PCS (B)
(A)
(B)
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urinary or plasma catecholamines, and their metabolites, as well as 
blood pressure. This suggests that a reduction of OSA-related stress 
by CPAP decreases sympathetic activity (catecholamines) and con-
sequently blood pressure. These findings lend further support for 
the intermediary role of sympathetic activity in the relationship be-
tween OSA-related stress and hypertension.
The impact of CPAP both on catecholamines and blood pressure 
has previously been debatable due to inconsistent findings. Forest plots 
in this analysis revealed high inter-study heterogeneity which may be 
explained by a variation in study designs and patient characteristics. 
For example, inclusion criteria of baseline blood pressure or severity of 
OSA may differ and other factors such as antihypertensive medications 
and duration of CPAP treatment are also likely to vary between studies.
The reduction in blood pressure observed in this analysis is 
consistent with findings from previous meta-analyses on CPAP and 
blood pressure.7,8,49,50 Although the reduction of systolic blood pres-
sure is relatively small (about 5-7.5 mmHg), this is clinically relevant 
in reducing stroke incidence.51
We found studies from existing literature reported a variety 
of methods of measurements, either urinary or plasma and cat-
echolamines or their metabolites, but the majority reported uri-
nary noradrenaline. The application of urinary catecholamines and 
metadrenalines or plasma metadrenaline depends on the degree of 
risk of an individual to have catecholamine-secreting tumor; urinary 
method which has high specificity (98%) is suggested for testing low-
risk patients, while plasma method (high sensitivity: 97%) is suggested 
for high-risk patients.52 Albeit, we found that CPAP had very similar 
effects on the reduction of all catecholamines and their metabolites.
In this study, we analyzed both RCTs and PCS and observed CPAP 
to have overall effects both on the reduction of catecholamine levels 
and blood pressure, which is consistent with observations made by 
Benson and Hartz.53 We observed that reductions in blood pressure 
appear to be higher in PCS than those in RCTs but not able to clarify 
the underlying reasons for these differences, but bias in selection of 
participants and CPAP treatment regimen may contribute.
It would be of interest to examine the effects of CPAP on heart 
rate in response to the reduction of catecholamines. However, only 
15 studies reported heart rate at baseline (Appendix S1) and only one 
studied changes in heart rate in relation to CPAP treatment.21 Heart 
rate was therefore not included as an outcome measure in our study.
There are certain limitations identified in this study, as expected 
for a meta-analysis. These include different methods of measuring 
catecholamines and their metabolites.
There were also varying methods applied to control groups in 
the RCTs, and some received no treatment while other received 
sham CPAP treatment. This may introduce a risk of bias since sham 
CPAP treatment has been shown to have greater influences on the 
results than non-treatment,54 which may underestimate the effect 
of CPAP on catecholamines and blood pressure.55 Further bias may 
also arise from the inability to disguise sham CPAP from patients in 
RCTs; about two-thirds of patients are able to determine whether 
they were receiving sham CPAP or therapeutic CPAP. The num-
bers of participants also vary widely between studies, while CPAP 
treatment duration ranges from one night to one year which would 
contribute to significant inter-study heterogeneity. There was a 
low representation of female participants relative to the overall 
prevalence of women with OSA56; thus, the findings from this 
study should be interpreted cautiously in the female population.
4  | CONCLUSIONS
CPAP treatment in patients with OSA reduces catecholamines lev-
els and blood pressure suggesting sympathetic activity plays an 
F I G U R E  4   Risk of bias of RCTs evaluated by Cochrane Collaboration's tool (A) and risk of bias of PCS evaluated by ROBINS-I tool (B)
(A) (B)
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intermediary role in the relationship between OSA-related stress 
and hypertension.
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